64 results about "Anticoagulation Agents" patented technology

The invention discloses blood component single sampling equipment capable of monitoring in real time in the field of blood treatment equipment. The equipment comprises a blood sampling module, a centrifugal separation module, a component collection module and an anticoagulant conveying module, and further integrates a multi-dimensional real-time monitoring system and a closed-loop self-adaptive regulation and control module. The multi-dimensional real-time monitoring system comprises an online micro-fluidic component detection unit, a physiological parameter monitoring unit and an equipment operation monitoring unit, can realize real-time online detection of blood component purity, cell activity and pollutant residue in the separation process, and synchronously monitors circulation physiological parameters of a blood donor and an equipment operation state at the same time; the closed-loop self-adaptive regulation and control module can dynamically adjust parameters such as the centrifugal rotating speed, the fluid pump speed and the anticoagulant ratio according to real-time monitoring data, and precise closed-loop control over the separation process is achieved. The quality stability of blood single-sampling components can be remarkably improved, meanwhile, the operation risk is greatly reduced, and the method is suitable for clinical blood component single-sampling and preparation scenes.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

To provide a factor Xa reagent.SOLUTION: Exemplary compositions include Factor Xa, a substrate, one or more guanidine derivatives, and in some cases heparin. An exemplary method of detecting an anticoagulant in a sample includes combining or contacting a composition with a sample and measuring factor Xa activity based on substrate status. The composition modulates the activity of factor Xa in the sample, and the modulation includes a reduction in the rate of clotting of the sample caused by factor Xa. The presence of an anticoagulant is based on the activity of factor Xa.SELECTED DRAWING: None

The application relates to the technical field of blood cell separation machines, in particular to a blood cell separation machine device for hematology nursing, which comprises a stirring mechanism, a feeding mechanism, a drawing mechanism, a centrifugal mechanism and a separation mechanism. The upper end of the stirring mechanism is provided with the feeding mechanism, the lower end of the feeding mechanism is provided with the drawing mechanism, the lower end of the drawing mechanism is provided with the centrifugal mechanism, and the centrifugal mechanism is provided with the separation mechanism at one end. The rotating stirring blade can uniformly mix blood and anticoagulant, preventing the blood from coagulating before centrifugation. The second sliding block and the first connecting pipe are in sliding cooperation, so that the anticoagulant can be automatically and quantitatively added into the cylinder. The second sleeve can draw the blood in the cylinder to the test tube when the first motor stops rotating. The sliding pipe and the second fixed block can quickly take out the separated blood plasma. The third sliding block can be pulled outward to take out the remaining blood cells conveniently and quickly.

Provided herein are devices, systems, methods, and compositions, including compositions for coupling to a surface of an implantable article, the compositions comprising an anticoagulant comprising a direct factor Xa inhibitor and at least one of (a) an antiplatelet drug, (b) an anticoagulant comprising a direct factor IIa inhibitor, and (c) an anti-inflammatory drug comprising colchicine.

The invention belongs to the technical field of clinical medicine, and relates to a method for extracting autologous platelet-rich plasma, which comprises the following steps of: adding an anticoagulant into an injector I in advance, then extracting autoblood, uniformly mixing for 3-4 times back and forth by virtue of an injector II, then centrifuging for 10 minutes at the speed of 1,500 revolutions per minute, sucking the platelet-rich plasma in the injector I by virtue of an injector III, and extracting the platelet-rich plasma in the injector II by virtue of an injector III. And centrifuging again, and discarding the supernatant by using an injector IV to obtain a high-concentration PRP finished product. According to the extraction method, in the extraction process, blood is uniformly mixed for 3-4 times back and forth between an injector I and an injector II, and the blood is centrifuged for 10 minutes at the speed of 1500 r / min in the first centrifugation process, so that the platelet concentration in the finally extracted PRP is remarkably improved compared with the platelet concentration in peripheral blood; the red blood cells reach the quality control target, the white blood cells are obviously reduced, and a set of standardized autologous platelet-rich plasma clinical extraction method which is simple in extraction device, low in consumable cost, simple to operate and high in extraction concentration is formed.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

The invention relates to the field of blood detection reagents, in particular to a blood free DNA stabilizer and application thereof. Every 100 ml of the blood free DNA stabilizer comprises 0.5-5 g of a buffer agent, 2-20 g of an aldehyde fixing agent, 15-20 g of an anticoagulant, 10-50 g of a cell stabilizer, 2.5-12.5 g of a nuclease inhibitor, and the balance of ultrapure water. The pH value of the blood free DNA stabilizer is 6.8 to 7.8; the cell stabilizer is selected from one or two or more than two of polysucrose-50, polysucrose-70, polysucrose-400, polyethylene glycol-4000, polyethylene glycol-6000, polyethylene glycol-8000 and glycine betaine. Preferably, the cell stabilizer is selected from polysucrose-70, and every 100 ml of the blood free DNA stabilizer contains 10 g of polysucrose-70. The stabilizer provided by the invention is low in toxicity and low in cost, and can maintain free DNA stability and inhibit blood cell genome release at normal temperature for 10 days, so that the storage cost and the transportation cost of a blood sample are effectively reduced, and the detection accuracy of the blood free DNA is improved.

The embodiments herein provide hemostatic compositions, methods, and kits comprising composite polymer particles. Upon contact with blood or other physiological fluids, the composite particles adsorb fluid and aggregate into a shape-retentive mass that halts bleeding. In certain embodiments, the particles comprise polymers of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, or combinations thereof. The particles may be used alone or blended with additional hemostatic agents. Methods of inducing hemostasis are provided for diffuse oozing, or surgical, mucosal, organ surface, fragile tissue or traumatic bleeding, including in patients receiving anticoagulant or antiplatelet therapy. Kits comprising sterile packages of composite particles, optionally with applicators, substrates, or sprays, are disclosed. The compositions exhibit intrinsic hemostatic activity and synergistically enhance the performance of conventional hemostats, achieving rapid clotting. After hemostasis is achieved, the compositions remain in situ as a conforming protective layer, reducing the need for additional covering materials and decreasing risk of re-bleeding.

The invention discloses a blood sampler, and relates to the technical field of blood sampling. Comprising a blood collection piece, a flow guide piece is installed in the blood collection piece, and the flow guide piece is used for guiding blood to the bottom of the blood collection piece; the blood collection piece is sleeved with a lifting adjusting piece; a lifting isolation piece is mounted in the blood collection piece; the lifting isolation piece magnetically attracts the lifting adjusting piece; a puncture sampling piece is mounted on the blood collection piece; an anticoagulant is conveniently drained to the inner side of the drainage tube by utilizing the lifting isolation piece, and the flow guide piece can be used for draining blood, so that the blood can be conveniently and directly discharged from an anticoagulant solvent at the bottom of the blood collection tube during collection, and the anticoagulant effect is ensured; the problems that according to an existing blood sampler, direct anticoagulation drainage to a solvent is not convenient, clear liquid is not convenient to isolate, protect and separate, and butt joint is tedious through manual single-hand operation are solved.

The invention relates to a composition for stabilizing a human prothrombin complex and application of the composition. The composition comprises an anticoagulant and a protective agent, the anticoagulant is heparin and / or a pharmaceutically acceptable salt thereof; the protective agent is selected from arginine and / or histidine and one or more of their respective pharmaceutically acceptable salts, and the ratio of the anticoagulant to the protective agent is (4.5-9.5) IU: (0.02-0.04) g. The activity of FII, FVII, FIX and FX of the prothrombin complex preparation prepared by adopting the composition for stabilizing the human prothrombin complex provided by the invention is not obviously reduced even under the condition of high temperature (40 + / -2 DEG C), and the activity of the FII, the FVII, the FIX and the FX is not obviously reduced after the prothrombin complex preparation is stored at the high temperature for at least 24 months. The biological activity index of the prothrombin complex preparation still meets the clinical use standard.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by anticoagulants such as an Xa factor inhibitor, and has the characteristics of broad spectrum and high efficiency.

Provided herein are compositions comprising (1) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), a calcium channel blocker, and a sodium channel blocker and (2) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), and a sodium channel blocker, and uses of such compositions for stabilizing components in a blood sample.

The utility model relates to a separation device for injectable concentrated growth factors, which makes up the defects of the prior art in the preparation of injectable CGF, such as incapability of separation caused by blood coagulation in the preparation process, and incapability of slow release of growth factors due to inhibition of formation of a fibrous protein scaffold by using an anticoagulant. After blood sampling, blood is injected into the lower cavity of the separation device, PPP, CGF and RBC are obtained through a specific centrifugal program, the first piston assembly is pushed to enable the PPP on the upper layer to enter the upper cavity, the upper cover body is moved downwards to enable the third barrel to be communicated with the lower cavity, the first piston assembly is moved upwards to enable the CGF to enter the third barrel, and separation can be completed. During separation, only the piston needs to be pushed up and the upper cover body needs to be moved downwards, operation is simple, samples do not need to be transferred, the separation process is isolated from the outside, and safety is high; the prepared CGF can continuously and slowly release various autologous growth factors, and is beneficial to playing a continuous role in a long-term tissue repair process.

The invention provides a preparation method of a canine autologous platelet-rich fibrous protein membrane, which comprises the following steps of: collecting canine autologous vein blood by using a vacuum blood collection tube with a preset anticoagulant, centrifuging, discarding supernatant, centrifuging again, discarding lower erythrocytes, and collecting the canine autologous platelet-rich fibrous protein membrane. And placing the obtained dog autologous platelet-rich fibrous protein gel between double stainless steel grids, and pressing to obtain the dog autologous platelet-rich fibrous protein membrane. The invention also provides an application of the prepared autologous platelet-rich fibrin membrane for dogs, wherein the autologous platelet-rich fibrin membrane is used for preparing drugs for wound repair. According to the invention, the autologous platelet-rich fibrin therapy is used for preparing the drug for repairing the dog wound for the first time, and through a triple mechanism of replacing antibiotics by autoimmune regulation, promoting healing by sequential release of growth factors and a zero-allergen biological scaffold, the healing period is shortened while the public health risk is avoided, and the healing effect is improved. The method is an innovative scheme with safety, effectiveness and sustainability.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by anticoagulants such as a thrombin direct inhibitor, and has the characteristics of broad spectrum and high efficiency.

This invention belongs to the field of lymphoma screening technology, specifically relating to a flow cytometry screening method for lymphoma. The method consists of the following steps: (1) taking an animal bone marrow or peripheral blood sample and placing it in a blood collection tube containing an anticoagulant, mixing until no clots remain, to obtain the sample to be tested; (2) adding 380 μL of white blood cells to the sample to be tested, stirring for 2-5 seconds, letting it stand for 5-10 minutes until the cell suspension completely turns brownish-red, then diluting it to obtain a sample containing 1×10⁻⁶ cells per 20 μL of the sample to be tested. 6 ~2×10 6 (3) Take NHL-1 and NHL-2 test tubes, add the test sample from step (1), add 2 mL of ammonium chloride hemolysin, shake to mix, incubate in the dark for 15-20 min, add the first physiological saline, centrifuge at 1500-2000 rpm for 3-5 min, discard the supernatant, shake to mix, add the first physiological saline again for washing, centrifuge at 1500-2000 rpm for 5-8 min, discard the supernatant, and retain about 100 μL of cell suspension; This invention can quickly screen for lymphoma.

The present invention discloses an anti-factor V antibody useful as an anticoagulant agent and as a tool for diagnostic and research applications. The antibody or its fragments can be conveniently used as anticoagulant agents inhibiting Factor V and / or Factor Va, particularly to reduce clot formation and associated thrombotic events, or they can be used in vitro to measure the levels of Factor V in a blood sample. Other aspects of the invention regard nucleic acids encoding the antibody or fragments thereof as well as expression vectors and host cells containing them.

The invention discloses a sample collection device for blood detection, and belongs to the technical field of blood collection. By starting a swing assembly, an upper supporting assembly and a lower supporting assembly outside a stand column integrally do reciprocating revolution, and an outer gear ring can be subjected to meshing driving force of an inner gear ring in the reciprocating revolution process and rotate around the axis of the outer gear ring; the rotation of the outer gear ring drives the test tube rack and the blood sampling test tubes in the test tube rack to synchronously rotate, and in the reciprocating revolution process of the outer gear ring, the test tube rack drives the internal sample test tubes to rotate again, so that the blood sampling test tubes simultaneously perform reciprocating revolution and continuous reciprocating rotation around the stand column in a refrigeration environment; a blood sample in the test tube generates continuous dynamic flow, the dynamic flow can promote uniform mixing of blood and an anticoagulant in the test tube, local aggregation of the anticoagulant is avoided, precipitation and condensation of the sample are effectively inhibited from the physical level, uniform and stable components of the sample are guaranteed, and the accuracy and consistency of a detection result are improved.

This invention provides a medication supply device that is not easily limited by the packaging materials of medications such as heparin and can use a single package of medication for multiple treatments. The medication supply device supplies medication to a blood circuit of a blood purification device for purifying blood. The medication supply device includes: a composition holding section capable of introducing an anticoagulant contained in a container from a container and holding a composition containing at least the introduced anticoagulant; and a connecting section connecting the composition holding section to the blood circuit, capable of exporting the composition from the composition holding section to the blood circuit.

The present disclosure is in the field of coagulation diagnostics and relates to a method for excluding anticoagulants from the group of factor XIa inhibitors in a patient sample.

Abstract: An object of the present invention is to provide a hollow fiber membrane that achieves both inhibiting adhesion of blood coagulation components to the surface of the membrane and having the high-efficiency performance of adsorptively removing inflammatory cells, inflammatory cytokines, and the like. The present invention provides a hollow fiber membrane including an anti-coagulant, and having a surface that comes into contact with a liquid to be treated, wherein the surface has an arithmetic-average roughness (Ra) of 0.10 to 0.80 µm in the radial direction.

The application discloses a kind of composite protein gels and preparation method thereof, its preparation method includes the following steps: with the blood collection tube with anticoagulant is collected blood;The above-mentioned blood is centrifuged at 300-700g centrifugal acceleration at room temperature 10-20min;After centrifugation, blood is transferred to biological safety cabinet, and the upper plasma layer is extracted, and then it is placed in-80 ℃ ultra-low temperature refrigerator and rapidly frozen, and the freezing time is 24-72h;Then, the frozen plasma is taken out, and freeze-drying treatment is carried out under the condition that the temperature is-55-65 ℃ and the pressure is 50-100Pa, and the freeze-dried plasma is prepared;Calcium chloride injection is added to the freeze-dried plasma at a volume ratio of 1:0.5-2, then reacted in a water bath at 60-90 ℃ for 5-15min, and removed to prepare.The protein gel can effectively solve the problem of easy skin stiffening, collapse, high in vivo absorption rate and poor filler stability caused by hyaluronic acid and autologous fat.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by antiplatelet drugs and other anticoagulants, and has the characteristics of broad spectrum and high efficiency.

Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and / or preventing thromboembolism and bleeding or clotting disorders. Also provided herein are methods for inhibiting thrombin in a cell using the compounds and compositions described herein.

The invention relates to the technical field of medical equipment, in particular to a blood anti-coagulation oscillation device for blood detection. According to the technical scheme, the swing device comprises a base, a swing mechanism is arranged on the top face of the base, the swing mechanism comprises a vertical plate, and a first motor is arranged on the right side of the vertical plate. According to the test tube placement device, the placement mechanism is arranged and can be conveniently adjusted according to the size of a test tube, so that the test tube placement device is suitable for placement of test tubes of different sizes, the equipment applicability is improved, the placement mechanism placed on a rocking plate can be conveniently and softly shaken by arranging a shaking mechanism, and the device is more similar to manual positive and negative inversion actions; according to the blood sampling device, blood and anticoagulant can be uniformly mixed, cells in the blood cannot be damaged due to too violent oscillation, a plurality of test tubes can be conveniently clamped and transferred at the same time by arranging the transfer mechanism, the workload and steps of blood sampling personnel can be reduced, the blood sampling efficiency can be improved, and the test tubes cannot be missed.

The utility model relates to the technical field of livestock and poultry blood collection, in particular to an anti-blood-coagulation livestock and poultry blood collection device which comprises a bottom plate and further comprises a collection barrel, a shaking mechanism and a feeding mechanism. The shaking mechanism comprises a moving plate and a shaking-up assembly, the putting mechanism comprises a discharging pipe, a hose, a pre-storage tank, a discharging assembly, an extrusion assembly and a transmission assembly, the shaking mechanism is arranged, the collecting barrel can be slowly shaken in a reciprocating mode at regular time, livestock and poultry blood in the collecting barrel can be evenly shaken, and by means of the putting mechanism, when the collecting barrel is shaken, the livestock and poultry blood in the collecting barrel can be evenly shaken. A proper amount of anticoagulant is put into the collecting barrel, so that blood coagulation of the livestock and poultry blood can be effectively avoided, and the livestock and poultry blood can be processed into food-grade products subsequently.

The application provides an abnormal blood sampling test data evaluation processing method and system of a blood sampling system. Wherein, the diffusion trajectory dynamics of the contact surface between the anticoagulant and blood in the blood collection tube is tracked in real time, the distortion characteristics of the dielectric response waveforms on both sides are synchronously collected by a capacitive sensor array to generate diffusion form parameters; the sound frequency modulated by the sound flow device triggered by the sudden change of curvature is analyzed to form a composite disturbance field; the capacitive axial scanning is performed on the disturbed mixed fluid to extract the phase angle offset and gradient mutation point coordinates to construct a three-dimensional dielectric anomaly map; the standard dielectric model is matched to locate the concentration gradient imbalance area and vortex decay area coordinate set to generate an anticoagulant anomaly index and a mixed defect matrix combined with the phase angle offset difference; the data anomaly degree evaluation function is established based on the anomaly index and the defect matrix, the clinical error threshold is dynamically associated, and the test evaluation result is output. The application can monitor the anticoagulant diffusion in real time and accurately evaluate the mixed quality error.

The utility model provides a blood collection device for slaughtering pork pigs, which relates to the field of blood collection equipment for slaughtering pork pigs, and comprises a collection component, a collection tank, a storage box for storing pig blood, an inclined plate and a guide pipe for guiding the pig blood, a discharge pipe for discharging the pig blood, a dosing unit and a conveying component, the stirring assembly is used for stirring the anticoagulant; the conveying assembly comprises a dispensing tank; the conveying assembly in the medicine adding unit is provided with the electric control regulating valve, the flow sensor and the PLC, the flow sensor can monitor the flow of the anticoagulant in real time and transmit data to the PLC, the PLC accurately controls the opening degree of the electric control regulating valve according to a preset value, it is ensured that the concentration of the anticoagulant in pig blood is appropriate, and the medicine adding efficiency is improved. Through automatic dosing control and stirring and mixing functions, the problems of pig blood coagulation and uneven mixing and inaccurate dosage caused by manual addition of an anticoagulant in a traditional collection device are solved, and the pig blood collection efficiency and quality are improved.